查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589281

大麗花疾病藥物市場：按治療類型、藥物、分銷管道和最終用戶分類 - 全球預測 2025-2030

Darier Disease Drugs Market by Treatment Type (Medication, Surgery), Drugs (Oral Retinoids, Topical Retinoids), Distribution Channel, End- User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年大麗花疾病治療市值為771.2億美元，預計到2024年將達到815.8億美元，複合年成長率為6.18%，預計到2030年將達到1173.6億美元。

毛囊角化病，又稱毛囊角化病，是一種罕見的遺傳性皮膚病，其特徵是身體上出現疣狀斑點。考慮到缺乏明確的治療方法，大麗花疾病治療藥物市場主要集中在控制症狀的治療選擇。局部和全身治療的目標是減輕皮膚病變的嚴重程度、控制感染疾病和緩解搔癢，通常會結合生活方式和飲食建議。對此類治療的需求正在增加，因為這種疾病是終生的並且會影響個人的生活品質。市場的應用範圍包括類類視色素A和皮質類固醇等組合藥物、非處方藥、基因治療和新配方研究。

主要市場統計
基準年[2023] 771.2億美元
預測年份 [2024] 815.8億美元
預測年份 [2030] 1173.6億美元
複合年成長率（%） 6.18%

該市場的成長要素包括持續的研發活動、對罕見疾病的認知不斷提高以及皮膚科領域的進步。診斷工具的改進也促進了早期檢測和治療，進一步支持市場成長。潛在的機會包括利用基因組學的突破來開發生技藥品和個人化醫療方法。抓住這些機會的研究包括與基因研究人員合作以及利用數位平台擴大病人參與。

儘管有這些機遇，市場仍面臨一些限制，例如藥物開發高成本、監管障礙以及由於患者群體有限而對罕見疾病進行臨床測試帶來的挑戰。此外，大眾和一些醫療專業人員對大麗花病缺乏認知和了解，阻礙了診斷和治療。

在創新和研究方面，對 CRISPR 等基因編輯技術的投資是一個很有前景的領域，它為遺傳疾病提供了治療潛力。擴大與皮膚科診所的合作夥伴關係，進行以患者為中心的研究並加強對患者教育的關注，可能會深入了解疾病進展和更有針對性的治療方法。儘管市場的本質仍然是利基市場，但透過精準醫學和治療方法的進步實現成長的途徑前景廣闊。

市場動態：揭示快速發展的大麗花疾病藥物市場的關鍵市場洞察

大麗花病藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 各國大麗花病的高風險
    • 加大開發新藥研發投入
    • 消費者意識不斷增強
  • 市場限制因素
    • 大麗花病藥物的報銷限制
  • 市場機會
    • 治療毛里爾病的新型皮膚病製劑的出現
    • 完善供應鏈，強化藥品供應體系
  • 市場問題
    • 治療的複雜性和持續時間

波特的五力：駕馭大麗花疾病藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解大麗花病藥物市場的外部影響

外部宏觀環境因素在塑造大麗花疾病治療藥物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解大麗花疾病治療藥物市場的競爭狀況

對大麗花疾病治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣：大麗花疾病治療藥物市場供應商的績效評估

FPNV 定位矩陣是評估大麗花疾病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製大麗花疾病藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對大麗花疾病治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

它也回答重要問題，幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 經濟體中出現達裡爾氏症的高風險
      • 加大開發新藥研發投入
      • 意識提升
    • 抑制因素
      • 大麗花病藥物的有限退款
    • 機會
      • 針對達裡爾病的新型皮膚病製劑的出現
      • 改善供應鏈以增加藥品可得性
    • 任務
      • 治療的複雜性和持續時間
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章大麗花疾病治療藥物市場：依治療類型

  • 介紹
  • 藥品
  • 外科手術

第7章 大麗花疾病治療藥物市場：依藥物分類

  • 介紹
  • 口服類視色素
  • 局部類視色素

第8章大麗花疾病治療藥物市場：依通路分類

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章大麗花疾病治療藥物市場：依最終使用者分類

  • 介紹
  • 皮膚科醫生
  • 居家醫療
  • 醫院
  • 專科診所

第10章 北美和南美大麗花疾病治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太大麗花疾病藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲大麗花病藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Allergan plc
  • Bausch Health Companies Inc.
  • BridgeBio Inc
  • Galderma Laboratories, LP
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Inc
  • Mayne Pharma Group Limited
  • Merck KGaA
  • Nimble Pharmaceuticals
  • Novartis AG
  • Recursion Pharmaceuticals, Inc.
  • Sigmapharm Laboratories, LLC
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
  • TOLMAR Inc.
Product Code: MRR-4659C8712C78

The Darier Disease Drugs Market was valued at USD 77.12 billion in 2023, expected to reach USD 81.58 billion in 2024, and is projected to grow at a CAGR of 6.18%, to USD 117.36 billion by 2030.

Darier Disease, also known as keratosis follicularis, is a rare, genetic skin disorder characterized by wart-like blemishes on the body. The Darier Disease drugs market focuses on treatment options that primarily manage symptoms, considering there is no definitive cure. The scope encompasses topical and systemic treatments intended to reduce the severity of skin lesions, manage infections, and alleviate itchiness, with products often used in conjunction with lifestyle and dietary recommendations. The necessity for such treatments is growing owing to the disease's life-long persistence and potential impact on individuals' quality of life. Applications in this market range from prescription medications such as retinoids and corticosteroids to over-the-counter solutions and ongoing research into gene therapy and novel drug formulations.

KEY MARKET STATISTICS
Base Year [2023] USD 77.12 billion
Estimated Year [2024] USD 81.58 billion
Forecast Year [2030] USD 117.36 billion
CAGR (%) 6.18%

The key influencing growth factors in this market include ongoing R&D activities, increasing awareness about rare diseases, and advancements in dermatological science. Improved diagnostic tools also facilitate early detection and treatment, further fueling market growth. One potential opportunity is the development of biologics and personalized medicine approaches, leveraging breakthroughs in genomics. Recommendations to seize these opportunities include collaborations with genetic researchers and leveraging digital platforms for broader patient engagement.

Despite these opportunities, the market faces limitations such as the high cost of drug development, regulatory hurdles, and the challenges associated with conducting clinical trials for rare diseases due to limited patient populations. Moreover, there is a lack of awareness and understanding of Darier Disease among the general public and some healthcare professionals, which can hinder diagnosis and treatment.

For innovation and research, investing in gene-editing technologies like CRISPR, which offers potential therapy for genetic disorders, stands out as a promising area. Expanding partnerships with dermatology clinics to conduct patient-centric research and increasing the focus on patient education could provide insights into the disease's progression and better-targeted treatments. The market's nature remains niche, but with promising avenues for growth through precision medicine and therapeutic advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Darier Disease Drugs Market

The Darier Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High risk of Darier diseases in economies
    • Rising investments in R&D to develop novel drugs
    • Increasing awareness among consumers
  • Market Restraints
    • Limited reimbursement for Darier disease drugs
  • Market Opportunities
    • Emergence of novel dermatological preparations for Darier disorders
    • Improvements in the supply chain to enhance the availability of drugs
  • Market Challenges
    • Complexity and prolonged nature of treatment

Porter's Five Forces: A Strategic Tool for Navigating the Darier Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Darier Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Darier Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Darier Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Darier Disease Drugs Market

A detailed market share analysis in the Darier Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Darier Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Darier Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Darier Disease Drugs Market

A strategic analysis of the Darier Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Darier Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc, Bausch Health Companies Inc., BridgeBio Inc, Galderma Laboratories, L.P, GlaxoSmithKline plc, Glenmark Pharmaceuticals Inc, Mayne Pharma Group Limited, Merck KGaA, Nimble Pharmaceuticals, Novartis AG, Recursion Pharmaceuticals, Inc., Sigmapharm Laboratories, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, and TOLMAR Inc..

Market Segmentation & Coverage

This research report categorizes the Darier Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medication and Surgery.
  • Based on Drugs, market is studied across Oral Retinoids and Topical Retinoids.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End- User, market is studied across Dermatologist, Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High risk of Darier diseases in economies
      • 5.1.1.2. Rising investments in R&D to develop novel drugs
      • 5.1.1.3. Increasing awareness among consumers
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement for Darier disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of novel dermatological preparations for Darier disorders
      • 5.1.3.2. Improvements in the supply chain to enhance the availability of drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity and prolonged nature of treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Darier Disease Drugs Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Surgery

7. Darier Disease Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Oral Retinoids
  • 7.3. Topical Retinoids

8. Darier Disease Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Darier Disease Drugs Market, by End- User

  • 9.1. Introduction
  • 9.2. Dermatologist
  • 9.3. Homecare
  • 9.4. Hospitals
  • 9.5. Specialty Clinics

10. Americas Darier Disease Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Darier Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Darier Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allergan plc
  • 2. Bausch Health Companies Inc.
  • 3. BridgeBio Inc
  • 4. Galderma Laboratories, L.P
  • 5. GlaxoSmithKline plc
  • 6. Glenmark Pharmaceuticals Inc
  • 7. Mayne Pharma Group Limited
  • 8. Merck KGaA
  • 9. Nimble Pharmaceuticals
  • 10. Novartis AG
  • 11. Recursion Pharmaceuticals, Inc.
  • 12. Sigmapharm Laboratories, LLC
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Teva Pharmaceutical Industries Ltd
  • 15. TOLMAR Inc.

LIST OF FIGURES

  • FIGURE 1. DARIER DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DARIER DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DARIER DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DARIER DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DARIER DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DARIER DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY ORAL RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY TOPICAL RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY DERMATOLOGIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DARIER DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DARIER DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DARIER DISEASE DRUGS MARKET SIZE, BY END- USER, 2018-2030 (USD MILLION)
  • TABLE 190. DARIER DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. DARIER DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023